Crinetics (CRNX) CCO option exercise and 10b5-1 share sale disclosed

Rhea-AI Filing Summary

Crinetics Pharmaceuticals’ Chief Commercial Officer, Isabel Kalofonos, reported routine insider transactions. On January 5, 2026, she exercised a stock option for 2,500 shares of common stock at an exercise price of $40.59 per share, converting derivative securities into common stock. That same day, she sold 2,500 shares of common stock in an open‑market transaction at $55.00 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on June 7, 2025.

Following these transactions, Kalofonos directly beneficially owned 834 shares of common stock, which include shares acquired under the company’s employee stock purchase plan, and held 97,500 stock options after the reported option exercise.

Insider Trade Summary

Net Seller: 2,500 shares ($137,500)

Net Sell 3 txns

Insider Kalofonos Isabel

Role Chief Commercial Officer

Sold 2,500 shs ($138K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,500	$0.00	--
Exercise	Common Stock	2,500	$40.59	$101K
Sale	Common Stock	2,500	$55.00	$138K

Holdings After Transaction: Stock Option (Right to Buy) — 97,500 shares (Direct); Common Stock — 3,334 shares (Direct)

Footnotes (1)

1. Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2025. The common stock was sold by the Reporting Person in an open market transaction on the transaction date, at a sale price of $55.00 per share. The option is exercisable as follows: 25% of the shares subject to the option vested on December 16, 2025, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalofonos Isabel

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		M		2,500	A	$40.59	3,334(1)	D
Common Stock	01/05/2026		S(2)		2,500	D	$55(3)	834	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$40.59	01/05/2026		M			2,500	(4)	01/10/2035	Common Stock	2,500	$0	97,500	D

Explanation of Responses:

1. Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan.

2. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2025.

3. The common stock was sold by the Reporting Person in an open market transaction on the transaction date, at a sale price of $55.00 per share.

4. The option is exercisable as follows: 25% of the shares subject to the option vested on December 16, 2025, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CRNX report for Isabel Kalofonos?

The Chief Commercial Officer, Isabel Kalofonos, exercised a stock option for 2,500 shares of Crinetics Pharmaceuticals common stock and sold 2,500 shares in the open market on January 5, 2026.

At what prices did the CRNX insider option exercise and sale occur?

Kalofonos exercised stock options at an exercise price of $40.59 per share and sold 2,500 common shares at a sale price of $55.00 per share in an open‑market transaction.

Was the CRNX insider share sale done under a Rule 10b5-1 plan?

Yes. The 2,500‑share sale by Isabel Kalofonos was effected automatically under a Rule 10b5‑1 trading plan that she adopted on June 7, 2025.

How many CRNX shares does the insider own after these transactions?

After the reported transactions, Kalofonos directly beneficially owned 834 shares of Crinetics Pharmaceuticals common stock, including shares acquired through the employee stock purchase plan.

How many CRNX stock options does Isabel Kalofonos hold after the filing?

Following the 2,500‑share option exercise, Kalofonos held 97,500 stock options (stock options with a right to buy shares) directly.

How do the vesting terms work for the reported CRNX stock option?

For the reported option, 25% of the shares vested on December 16, 2025, and the remaining shares vest in 36 equal monthly installments, subject to Kalofonos’s continued employment with Crinetics Pharmaceuticals on each vesting date.